Overcoming Challenges of Anti-Drug Antibody (ADA) Assays Using Single Molecule Counting (SMC<sup>®</sup>) Technology
MilliporeSigma SPONSORED CONTENT

Overcoming Challenges of Anti-Drug Antibody (ADA) Assays Using Single Molecule Counting (SMC®) Technology

Overcoming Challenges of Anti-Drug Antibody (ADA) Assays Using Single Molecule Counting (SMC®) Technology

All biological therapeutics have the potential to induce an immune-mediated response ranging from benign to severe adverse effects. These effects can encompass diminished clinical efficacy of the biotherapeutic being administered due to hypersensitivity, allergic reactions, or even cytokine storms. Consequently, regulatory agencies are looking to understand the implications of immunogenicity and are directing the industry to integrate programs for immunogenicity risk management during the pre-clinical and clinical phases of drug development. Download this application note to see how ultrasensitive SMC® assays are helping researchers overcome the challenges of immunogenicity testing.

Download Now

    Please fill out the information below to download the content. If you are already registered, or have requested a quote before, and this information will be filled out for you.
  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.